MedTrace Logo

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NCT05626530 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-04-10

No results posted yet for this study

Summary

This is a research study to test the tolerability and clinical effectiveness of the study drug, Letermovir (LET), when used as secondary prophylaxis following treatment of Cytomegalovirus (CMV) infection and disease in a solid organ transplant recipient.

This study is an open label trial in which Letermovir will be prescribed to prevent the recurrence of CMV infection and disease in a solid organ transplant recipient following treatment of CMV infection or disease.

Conditions

  • Cytomegalovirus Infections
  • Infection in Solid Organ Transplant Recipients
  • Neutropenia
  • Antiviral Toxicity

Interventions

DRUG

Letermovir

Open label 480 mg given daily for 60 days

Sponsors & Collaborators

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Jennifer K Chow, MD, MS · Tufts Medical Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2025-12-15
Completion
2025-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05626530 on ClinicalTrials.gov